Seminar
7 June
2022

Dissecting and modulating reactive anti-tumor immunity in human cancers

Le 7 June - 10h-23h
Description

Reinvigoration of tumor-specific T cells by cancer immunotherapies, in particular PD-1/PD-L1 blocking agents, has been the most important innovation in the treatment of patients with cancer. Nevertheless, durable clinical benefit is currently limited to a small number of patients. At present, the immunological alterations that occur in human cancers upon PD-1 blockade are not well understood. Using patient-derived organotypic tumor models, we investigate how tumor immune composition and architecture influence immunotherapy response and how distinct treatments can change immune activity in a tumor. The observed immunotherapy-induced changes can then be linked to the inherent qualities of a tumor and its infiltrating immune populations, thereby contributing to the identification of determinants for effective response to immunotherapy and to the development of novel treatment strategies.

Orateurs
Daniela
Thommen
MD, PhD
Netherlands Cancer Institute - Amsterdam, Netherlands
Invité(es) par
Christina
Metoikidou
Institut Curie
Sebastian
Amigorena
Institut Curie